Effect of Low-Dose Statins in Addition to Standard Therapy on Brain Perfusion and Neurocognitive Performance in Patients with Major Depressive Disorder

Simple item page
dc.contributor.authorMassardo, Teresa
dc.contributor.authorQuintana, Juan C.
dc.contributor.authorRisco, Luis
dc.contributor.authorCorral, Sebastian
dc.contributor.authorSpuler, Jane
dc.contributor.authorVicentini, Daniel
dc.contributor.authorCastro-Munoz, Gabriel
dc.contributor.authorRiedel, Byron
dc.contributor.authorVilla, Carolina
dc.contributor.authorPereira, Jaime I.
dc.date.accessioned2025-01-20T21:01:19Z
dc.date.available2025-01-20T21:01:19Z
dc.date.issued2022
dc.description.abstractIntroduction: Major depressive disorder (MDD) is a prevalent condition which has a well-known association with ischemic cardiomyopathy, probably explained by an inflammatory mediator mechanism. Statins, besides reducing cholesterol production, have pleiotropic effects including anti-inflammatory activity. The goal was to evaluate the effect of statins as an addition to standard therapy on mood status, brain perfusion, and neurocognitive performance in MDD. Methods: We studied 20 MDD patients with brain single-photon emission tomography and Cambridge Neuropsychological Test Automated Battery (CANTAB), half randomized to 10 mg of Rosuvastatin or placebo, in addition to selective serotonin reuptake inhibitors (SSRIs) therapy and being reevaluated 3 months later. The images were compared using Statistical Parametric Mapping; clinical scores (Hamilton Depression Score with 17 items and Beck's Depression Inventory) as well as neurocognitive parameters were applied as covariances (CoV) to estimate regional cerebral blood flow (rCBF) changes with both therapies. Results: Clinical scores decreased in both groups (p = 0.0001); Beck's presented a larger decrease with statins. We observed significantly rCBF changes expressed as significant larger clusters of voxels (p < 0.05) in the pre/subgenual anterior cingulate plus orbitofrontal cortex and a small area in the posterior cingulate gyrus in the statins group, whereas it was not observed with placebo, when using clinical scores as CoV. A similar pattern of rCBF changes was present with emotions recognition, attentional, paired associates learning, spatial planning, and working memory tasks. Conclusion: Short-term use of low-dose statins in MDD patients under SSRIs results in important rCBF changes in key mood associated areas to improvement in neurocognitive performance. These findings, even though demonstrated in a small sample, could open a new therapeutic tool in the comprehensive management of this disorder.
dc.fuente.origenWOS
dc.identifier.doi10.1159/000521104
dc.identifier.eissn1423-0224
dc.identifier.issn0302-282X
dc.identifier.urihttps://doi.org/10.1159/000521104
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92857
dc.identifier.wosidWOS:000894015500003
dc.issue.numero4
dc.language.isoen
dc.pagina.final285
dc.pagina.inicio271
dc.revistaNeuropsychobiology
dc.rightsacceso restringido
dc.subjectStatins
dc.subjectMajor depression
dc.subjectRegional cerebral blood flow
dc.subjectNeurocognition
dc.subjectSingle-photon emission tomography
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffect of Low-Dose Statins in Addition to Standard Therapy on Brain Perfusion and Neurocognitive Performance in Patients with Major Depressive Disorder
dc.typeartículo
dc.volumen81
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas